Larimar Therapeutics Statistics
Total Valuation
LRMR has a market cap or net worth of $379.95 million. The enterprise value is $183.35 million.
| Market Cap | 379.95M |
| Enterprise Value | 183.35M |
Important Dates
The last earnings date was Thursday, May 14, 2026, before market open.
| Earnings Date | May 14, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
LRMR has 104.38 million shares outstanding. The number of shares has increased by 24.53% in one year.
| Current Share Class | 103.88M |
| Shares Outstanding | 104.38M |
| Shares Change (YoY) | +24.53% |
| Shares Change (QoQ) | +5.96% |
| Owned by Insiders (%) | 1.12% |
| Owned by Institutions (%) | 43.48% |
| Float | 59.98M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 2.40 |
| P/TBV Ratio | 2.40 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 4.29, with a Debt / Equity ratio of 0.02.
| Current Ratio | 4.29 |
| Quick Ratio | 4.21 |
| Debt / Equity | 0.02 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -109.83% and return on invested capital (ROIC) is -69.31%.
| Return on Equity (ROE) | -109.83% |
| Return on Assets (ROA) | -56.92% |
| Return on Invested Capital (ROIC) | -69.31% |
| Return on Capital Employed (ROCE) | -107.26% |
| Weighted Average Cost of Capital (WACC) | 8.66% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$2.34M |
| Employee Count | 71 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +35.32% in the last 52 weeks. The beta is 0.82, so LRMR's price volatility has been lower than the market average.
| Beta (5Y) | 0.82 |
| 52-Week Price Change | +35.32% |
| 50-Day Moving Average | 3.94 |
| 200-Day Moving Average | 3.99 |
| Relative Strength Index (RSI) | 51.40 |
| Average Volume (20 Days) | 1,860,974 |
Short Selling Information
The latest short interest is 8.05 million, so 7.71% of the outstanding shares have been sold short.
| Short Interest | 8.05M |
| Short Previous Month | 8.74M |
| Short % of Shares Out | 7.71% |
| Short % of Float | 13.42% |
| Short Ratio (days to cover) | 4.50 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -172.43M |
| Pretax Income | -166.01M |
| Net Income | -166.01M |
| EBITDA | -172.10M |
| EBIT | -172.43M |
| Earnings Per Share (EPS) | -$2.09 |
Balance Sheet
The company has $200.39 million in cash and $3.78 million in debt, with a net cash position of $196.61 million or $1.88 per share.
| Cash & Cash Equivalents | 200.39M |
| Total Debt | 3.78M |
| Net Cash | 196.61M |
| Net Cash Per Share | $1.88 |
| Equity (Book Value) | 158.03M |
| Book Value Per Share | 1.51 |
| Working Capital | 157.22M |
Cash Flow
In the last 12 months, operating cash flow was -$131.28 million and capital expenditures -$42,000, giving a free cash flow of -$131.32 million.
| Operating Cash Flow | -131.28M |
| Capital Expenditures | -42,000 |
| Depreciation & Amortization | 326,000 |
| Net Borrowing | n/a |
| Free Cash Flow | -131.32M |
| FCF Per Share | -$1.26 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
LRMR does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -24.53% |
| Shareholder Yield | n/a |
| Earnings Yield | -43.69% |
| FCF Yield | -34.56% |
Analyst Forecast
The average price target for LRMR is $15.11, which is 315.11% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $15.11 |
| Price Target Difference | 315.11% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 10 |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 1 |